Muscle-Derived Progenitor Cells for Bone Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments using myoblasts for tissue augmentation, particularly in bone tissue, face challenges such as low survival rates due to migration and/or phagocytosis, and limited compatibility with non-muscle tissues.
Innovation Solution
The use of muscle-derived progenitor cells (MDCs) that express specific markers like desmin, CD34, and Bcl-2, which can be isolated and enriched for long-term survival and compatibility with a wide range of host tissues, including bone.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If myoblasts are used for tissue augmentation in bone, then bone augmentation can be achieved, but cell survival rate is low due to migration and phagocytosis
Solution Approach 1:
The patent changes the cell type parameter from conventional myoblasts to muscle-derived progenitor cells (MDCs) with specific marker expressions (CD34+, Bcl-2+, desmin+). This parameter change results in cells with enhanced survival capabilities and reduced migration/phagocytosis, directly resolving the contradiction between achieving bone augmentation and maintaining cell survival rate.
Solution Approach 2:
The patent creates a specialized subset of muscle-derived cells that replicate the beneficial properties of stem cells (long-term survival, self-renewal) while avoiding their limitations. These MDCs are derived from adult muscle tissue and exhibit stem cell-like characteristics, effectively copying the survival advantage without the harmful migration and phagocytosis issues of conventional myoblasts.
2Adaptability or versatility
If conventional myoblasts are used for bone augmentation, then treatment can be administered, but compatibility with non-muscle tissues is limited
Solution Approach 1:
The patent demonstrates that muscle-derived progenitor cells possess universal compatibility with multiple host tissue types including bone, muscle, and other tissues. The MDCs express multiple surface markers (CD34, Bcl-2, desmin, Sca-1, Flk-1) that enable them to integrate and function across different tissue types, transforming them from tissue-specific cells to multi-functional therapeutic cells capable of augmenting various tissues including bone.
3Duration of action of stationary object
If muscle-derived progenitor cells are isolated and enriched, then long-term survival is achieved, but isolation and enrichment processes become more complex
Solution Approach 1:
The patent employs a multi-step isolation and enrichment process that segments the cell population based on differential adhesion characteristics. The process separates rapidly adhering cells from slowly adhering cells, then further enriches the slowly adhering population through selective plating and culture conditions. This segmentation approach systematically isolates the MDC subset with long-term survival properties while maintaining a manageable and reproducible process complexity.
Data Source
AI summary
The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.